London, UK, 26 June 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, following the exercise of employee share options by an ex-employee, application has been made to AIM for the admission of 6,238 new ordinary shares of 5 pence each..
hVIVO Plc (HVO.L) Announced that Enanta Pharmaceuticals, Inc. has revealed positive topline results from an RSV challenge study. The study demonstrated that Enanta's novel N-protein inhibitor, EDP-938, achieved highly statistically significant (p<0.001) reductions in viral load and in resolution of clinical symptoms compared to placebo in healthy adults infected with respiratory syncytial virus (RSV). The study was conducted at the company’s specialist clinical facility in London, using its industry leading RSV challenge study protocol.
RNS Number: 3913 C hVIVO plc 17 June 2019 hVIVO plc. London, UK- 17 June 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral challenge, acknowledges the announcement by Enanta Pharmaceuticals, Inc. of positive topline results from an RSV challenge study. The study demonstrated that...
London, UK, 14 June 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, following the exercise of employee share options by an ex-employee, application has been made to AIM for the admission of 15,344 new ordinary shares of 5 pence each..
London, UK, 31 May 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, all resolutions proposed at its Annual General Meeting, held at 10.00 am on 30 May 2019, were duly passed. Based in the UK, market leader hVIVO has conducted more than 50 clinical...
London, UK, 21 May 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, following the exercise of employee share options by an ex-employee, application has been made to AIM for the admission of 23,465 new ordinary shares of 5 pence each..
RNS Number: 2431 X hVIVO plc 26 April 2019 hVIVO plc. London, UK- 26 April 2019: hVIVO plc, announces that the following documents have been sent to shareholders. The AGM is scheduled to be held at 10.00 am BST on Thursday 30 May 2019 on 3 rd Floor, Queen Mary BioEnterprises Innovation Centre, 42 New Road, London, E1 2 AX..
hVIVO (HVO.L) 27.25p £23.64m hVIVO, an industry leading clinical development services business pioneering human disease models based upon viral challenge, announced its preliminary results for the year ended 31 Dec 2018. Revenue & Other Income up 10.5% to £13.6m (2017: £12.3m) Adjusted Loss Before Tax down 27.6% to £9.6m (2017: £13.2m) Loss Before Tax - £18.9m (2017: £14.8m) Cash and cash equivalents of £13.4m (2017: £20.3m) Research and development expense down 21% to £4.8m (2017: £6.1m) Current cost reduction programmes are forecasted to deliver improvements which will reduce operating expense by a total of £3.9m, across 2018, 2019 and 2020 Re-focussed services business model with strong pipeline of contract opportunities Good progress on business turnaround, R&D expense significantly reduced and focussed specifically on opportunities to support the enhancement of our development services Cost base and expenditure reductions implemented to support future growth and provide a pathway to cash generation Positive Phase IIb FLU-v results
hVIVO Plc (HVO.L) Announced, in its preliminary results for the year ended 31 December 2018, that revenues rose to £11.0 million from £10.9 million recorded in the previous year. Loss after tax widened to £16.8 million from £12.96 million.
RNS Number: 8739 V hVIVO plc 11 April 2019 hVIVO plc. London, UK- 11 April 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral challenge, today announces its preliminary results for the year ended 31 December 2018.. ·Revenue& Other Income up 10.5% to £13.6 million.
London, UK, 1 April 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, application has been made to AIM for the admission of 15,772 new ordinary shares of 5.0 p each in the Company.. The New Ordinary Shares have been allotted pursuant to the purchase...
hVIVO Plc (HVO.L) Announced that the company and its joint venture, Imutex Limited, will present at the Influenza Vaccines for the World conference on 2-4 April 2019 at the Royal College of Physicians of Edinburgh, Edinburgh, Scotland, UK. The IVW series is an international forum for world renowned experts in the field of influenza vaccines and related issues (adjuvants / delivery / vaccination strategies) to report on the latest data and trends associated with current and new influenza vaccines / technologies and their availability / delivery / implementation worldwide.
hVIVO and Imutex Limited to present at the Influenza Vaccines for the World conference at the Royal College of Physicians of Edinburgh, Scotland. London, UK 29 March 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, confirms that the Company and its joint...
London, UK, 21 March 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, an application has been made to the London Stock Exchange for the admission of 644,600 new ordinary shares of 5.0 p each following an exercise of options by a former employee of...
London, UK 8 March 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, will announce its preliminary financial results for the twelve months ended 31 December 2018 on Thursday 11 April 2019.. A presentation and webcast for analysts will be held at 9.00 am BST at...
RNS Number: 5414 O hVIVO plc 30 January 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 0122 O hVIVO plc 24 January 2019 HVIVO PLC. London, UK, 24 January 2019: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that as part of the Company's commitment to encouraging all employees to be shareholders in the business, a total of 1,689,258...
hVIVO Plc (HVO.L) Announced the positive result for the primary endpoint, following completion of analysis of samples by NIAID and additional results from the Phase IIb viral challenge study of FLU-v, (Study 004, NCT03180801). FLU-v is being developed by Imutex Limited, the company's 49% joint venture with the SEEK Group. The primary endpoint was to assess the incidence of MMID which is refined as evidence of viral shedding in nasopharyngeal swab samples and the presence of at least one symptom. The company added that these results together with the previously reported highly statistically significant reduction in symptoms endpoint (p=0.023) and performing better than placebo in a number of other key endpoints is evidence of the vaccine's protective effect.
hVIVO Plc
HVO.L
hVIVO Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    82.30M

Classification

Market Indices-

Locations

HQ
Queen Mary BioEnte Innovation Centre
42 New Road
London
E1 2AX
Watchlist